Keymed Biosciences Reports Impressive H1 2026 Financial Results and Business Milestones

On August 19, 2026, Keymed Biosciences (HKEX: 02162) unveiled its remarkable financial performance for the first half of 2026, concluding on June 30. The company's total revenue reached an impressive 617 million RMB, marking a significant advancement in its operational success. Notably, the flagship product, Kangyueda, generated 393 million RMB, showcasing a staggering 132% year-over-year increase. This success is attributed to the dedicated efforts of a commercial team nearing 500 members, effectively covering over 1,600 hospitals.

The collaboration revenues also contributed positively, totaling 224 million RMB, which primarily stemmed from milestone payments received from AstraZeneca. Such financial results highlight Keymed's strong recovery, with a profit of 122 million RMB achieved after a prior loss. Furthermore, the company has bolstered its cash reserves to a substantial 3.24 billion RMB, providing a solid foundation for future investments and developments.

An important highlight from the recent results is the inclusion of Kangyueda in the national list of essential medicines effective from September 1, 2026, further accelerating its market penetration into county-level and primary healthcare sectors.

Furthermore, Keymed's dynamic product pipeline has shown significant progress. Recent approval for market authorization requests for Stapokibart, designed to treat adolescent atopic dermatitis and nodular prurigo, has set the stage for future advancements. Ongoing phase III trials for pediatric atopic dermatitis and seasonal allergic rhinitis in adolescents emphasize Keymed's commitment to addressing pressing healthcare needs.

In a notable partnership, Ouro Medicines, a collaborator of NewCo, was acquired by Gilead and Lakefront on June 5, yielding Keymed an initial payment of $257 million, along with prospects of up to $610 million in future milestone payments and royalties. Lakefront is tasked with overseeing phase I/II studies on CM336/OM336, while Gilead handles registration trials, maintaining exclusive global marketing rights (excluding Greater China).

While discussing other developments, the phase III global clinical trial for CMG901/AZD0901 (a CLDN18.2 ADC) commenced at the beginning of 2026, with its first patient enrolled. The perioperative study has progressed into phase II, extending its application to biliary tract and pancreatic cancers.

Additionally, Keymed has recently treated its first patient with CM355/PRO-203 (CD20 x CD3) for scleroderma in June, with plans for further studies focused on B-cell related autoimmune diseases set to launch in 2026.

Highlighting the advancements in immunotherapy, CM512, the world’s first long-acting dual inhibitor with a half-life of 70 days, has successfully met all phase II evaluation criteria in treating CRSwNP. The treatment demonstrated rapid reductions in polyp size and maintained effectiveness six months post single injection, paving the way for phase III trials.

The ongoing phase II trial for CM336 (a bispecific antibody targeting BCMA/CD3) focused on light chain amyloidosis is actively enrolling patients. The designation of 'innovative treatment’ was granted last May. Recruitment for the phase I/II trial concerning autoimmune cytopenias has been completed, with the phase Ib trial for Sjögren’s syndrome starting in July.

Moreover, an IND application for the combination therapy of CM336 and CM313 (anti-CD38 monoclonal antibody) for the treatment of relapsed or refractory multiple myeloma has been accepted, underscoring Keymed’s strong pipeline.

Operating on six integrated platforms, Keymed's manufacturing capabilities in Chengdu feature a production capacity of 21,800 liters, with plans to expand with 24,000-liter stainless steel production lines soon.

As of June 30, Keymed employed 1,768 full-time staff, with 500 supporting the commercialization sector and 420 dedicated to research and clinical trials. On the occasion of its tenth anniversary, Keymed remains focused on its dual-pronged patient-centered strategy aiming to accelerate global innovation and generate lasting value.